Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 13, 2008. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of insider share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary shares by seven individuals on November 11, 2008, at a price of £12.15 per share through the Company's Share Reward Plan. Each individual acquired:
- 11 Ordinary shares under the partnership element (personal contribution).
- 11 Ordinary shares under the matching element (Company contribution).
The individuals involved are Mr. A P Witty, Mr. J S Heslop, Mr. S M Bicknell, Mr. E J Gray, Mr. D Learmouth, Mr. D S Redfern, and Ms. C Thomas.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: November 11, 2008.
- Share Price: £12.15 per Ordinary share.
- Participants: Seven senior executives and directors.
- Transaction Type: Routine acquisitions under the Share Reward Plan (both personal and company-matched contributions).
- Notification Date: The company and individuals were advised on November 12, 2008.